930 related articles for article (PubMed ID: 17803912)
1. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran.
Kim HM; Park BS; Kim JI; Kim SE; Lee J; Oh SC; Enkhbayar P; Matsushima N; Lee H; Yoo OJ; Lee JO
Cell; 2007 Sep; 130(5):906-17. PubMed ID: 17803912
[TBL] [Abstract][Full Text] [Related]
2. Two modes of ligand recognition by TLRs.
Brodsky I; Medzhitov R
Cell; 2007 Sep; 130(6):979-81. PubMed ID: 17889640
[TBL] [Abstract][Full Text] [Related]
3. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
Mishra V; Pathak C
J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
[TBL] [Abstract][Full Text] [Related]
4. Stable transduction of bovine TLR4 and bovine MD-2 into LPS-nonresponsive cells and soluble CD14 promote the ability to respond to LPS.
Sauter KS; Brcic M; Franchini M; Jungi TW
Vet Immunol Immunopathol; 2007 Jul; 118(1-2):92-104. PubMed ID: 17559944
[TBL] [Abstract][Full Text] [Related]
5. The Toll-like receptor 4 region Glu24-Pro34 is critical for interaction with MD-2.
Nishitani C; Mitsuzawa H; Hyakushima N; Sano H; Matsushima N; Kuroki Y
Biochem Biophys Res Commun; 2005 Mar; 328(2):586-90. PubMed ID: 15694388
[TBL] [Abstract][Full Text] [Related]
6. Studies of the TLR4-associated protein MD-2 using yeast-display and mutational analyses.
Mattis DM; Chervin AS; Ranoa DR; Kelley SL; Tapping RI; Kranz DM
Mol Immunol; 2015 Dec; 68(2 Pt A):203-12. PubMed ID: 26320630
[TBL] [Abstract][Full Text] [Related]
7. Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment.
Deguchi A; Tomita T; Ohto U; Takemura K; Kitao A; Akashi-Takamura S; Miyake K; Maru Y
Oncogene; 2016 Mar; 35(11):1445-56. PubMed ID: 26165843
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa.
Ohto U; Fukase K; Miyake K; Satow Y
Science; 2007 Jun; 316(5831):1632-4. PubMed ID: 17569869
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2.
Ohto U; Fukase K; Miyake K; Shimizu T
Proc Natl Acad Sci U S A; 2012 May; 109(19):7421-6. PubMed ID: 22532668
[TBL] [Abstract][Full Text] [Related]
10. Human MD-2 discrimination of meningococcal lipid A structures and activation of TLR4.
Zimmer SM; Zughaier SM; Tzeng YL; Stephens DS
Glycobiology; 2007 Aug; 17(8):847-56. PubMed ID: 17545685
[TBL] [Abstract][Full Text] [Related]
11. Myeloid differentiation 2 as a therapeutic target of inflammatory disorders.
Park SH; Kim ND; Jung JK; Lee CK; Han SB; Kim Y
Pharmacol Ther; 2012 Mar; 133(3):291-8. PubMed ID: 22119168
[TBL] [Abstract][Full Text] [Related]
12. Human TLR4 polymorphism D299G/T399I alters TLR4/MD-2 conformation and response to a weak ligand monophosphoryl lipid A.
Yamakawa N; Ohto U; Akashi-Takamura S; Takahashi K; Saitoh S; Tanimura N; Suganami T; Ogawa Y; Shibata T; Shimizu T; Miyake K
Int Immunol; 2013 Jan; 25(1):45-52. PubMed ID: 22962435
[TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of truncated human lipopolysaccharide-binding protein in Escherichia coli.
Kohara J; Tsuneyoshi N; Gauchat JF; Kimoto M; Fukudome K
Protein Expr Purif; 2006 Oct; 49(2):276-83. PubMed ID: 16839777
[TBL] [Abstract][Full Text] [Related]
14. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization.
Saitoh S; Akashi S; Yamada T; Tanimura N; Kobayashi M; Konno K; Matsumoto F; Fukase K; Kusumoto S; Nagai Y; Kusumoto Y; Kosugi A; Miyake K
Int Immunol; 2004 Jul; 16(7):961-9. PubMed ID: 15184344
[TBL] [Abstract][Full Text] [Related]
15. Penta-acylated lipopolisaccharide binds to murine MD-2 but does not induce the oligomerization of TLR4 required for signal transduction.
Tsuneyoshi N; Kohara J; Bahrun U; Saitoh S; Akashi S; Gauchat JF; Kimoto M; Fukudome K
Cell Immunol; 2006 Nov; 244(1):57-64. PubMed ID: 17420011
[TBL] [Abstract][Full Text] [Related]
16. Essential roles of hydrophobic residues in both MD-2 and toll-like receptor 4 in activation by endotoxin.
Resman N; Vasl J; Oblak A; Pristovsek P; Gioannini TL; Weiss JP; Jerala R
J Biol Chem; 2009 May; 284(22):15052-60. PubMed ID: 19321453
[TBL] [Abstract][Full Text] [Related]
17. Molecular Basis of the Functional Differences between Soluble Human Versus Murine MD-2: Role of Val135 in Transfer of Lipopolysaccharide from CD14 to MD-2.
Vašl J; Oblak A; Peternelj TT; Klett J; Martín-Santamaría S; Gioannini TL; Weiss JP; Jerala R
J Immunol; 2016 Mar; 196(5):2309-18. PubMed ID: 26826249
[TBL] [Abstract][Full Text] [Related]
18. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex.
Park BS; Song DH; Kim HM; Choi BS; Lee H; Lee JO
Nature; 2009 Apr; 458(7242):1191-5. PubMed ID: 19252480
[TBL] [Abstract][Full Text] [Related]
19. MD-2-dependent human Toll-like receptor 4 monoclonal antibodies detect extracellular association of Toll-like receptor 4 with extrinsic soluble MD-2 on the cell surface.
Tsukamoto H; Ihara H; Ito R; Ukai I; Suzuki N; Kimoto M; Tomioka Y; Ikeda Y
Biochem Biophys Res Commun; 2013 Oct; 440(1):31-6. PubMed ID: 24021278
[TBL] [Abstract][Full Text] [Related]
20. Cetacean Toll-like receptor 4 and myeloid differentiation factor 2, and possible cetacean-specific responses against Gram-negative bacteria.
Shishido R; Ohishi K; Suzuki R; Takishita K; Ohtsu D; Okutsu K; Tokutake K; Katsumata E; Bando T; Fujise Y; Murayama T; Maruyama T
Comp Immunol Microbiol Infect Dis; 2010 Dec; 33(6):e89-98. PubMed ID: 20434218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
